But mixed data and a previous failure provide reasons to be cautious.
The group’s purchase of Affiris’s Parkinson’s portfolio comes after stumbles from Roche/Prothena and Biogen.
Abbvie expects more Rinvoq data in ulcerative colitis while Astrazeneca takes on myasthenia gravis, and gene therapy is in play for Pfizer and Roche.
The failure of gosuranemab could bode ill for Abbvie’s ABBV-8E12 in particular.
Acumen is the latest player to take aim at amyloid, but competition is fierce.
Like Aduhelm this long-discontinued amyloid beta MAb reduced brain beta amyloid; so have several other industry projects.
A green light from the US regulator for aducanumab is a huge boost for Biogen, but not everyone will be celebrating.
Key catalysts approach for Orphazyme, Gemini and Immutep.
Lilly and Roche bask in the reflected glow of aducanumab's benign briefing documents.